Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.

Trial Details

NCT ID
NCT05775159
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Volrustomig
  • Bevacizumab
  • Lenvatinib
  • Rilvegostomig
  • Gemcitabine
  • Cisplatin
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Costa Mesa, California, United States|33.64113,-117.91867
  • Los Angeles, California, United States|34.05223,-118.24368
  • Orange, California, United States|33.78779,-117.85311
  • Miami Beach, Florida, United States|25.79065,-80.13005

Key Eligibility Criteria

  • Age ≥18 years at the time of signing the ICF.
  • Provision of a signed and dated written ICF.
  • Confirmed locally advanced or metastatic solid tumor specified in substudy based on histopathology.
  • Adequate organ and bone marrow function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →